Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter

Diabetic Medicine

Volumn 32, Issue 4, 2015, Pages 438-439

  Ryder, R E J ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO; TUMOR PROMOTER; GLUCAGON RECEPTOR; INCRETIN;

ARTICLE; BLADDER CANCER; CARDIOVASCULAR DISEASE; HISTOPATHOLOGY; HUMAN; INTERPERSONAL COMMUNICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); AGONISTS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; PANCREAS TUMOR; PANCREATITIS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCRETINS; MALE; PANCREATIC NEOPLASMS; PANCREATITIS; RECEPTORS, GLUCAGON;

EID: 84924709813     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12703     Document Type: Article

References (10)

1. Gale EAM. Pioglitazone: are rumours of its death exaggerated? Diabet Med 2015; 32: e9-e15.
2. Ryder REJ. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med 2015; 32: 305-313.
3. Ryder REJ. Pioglitazone - reports of its death are greatly exaggerated* - it is alive and ready to resume saving lives. Diabet Med 2015; 32: e9-e15.
4. Turner RM, Kwok CS, Chen-Turner C, Maduakar CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014; 78: 258-273.
5. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Med Assoc J 2012; 184: E675-E683.
6. He S, Tang Y, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumor Biol 2014; 35: 2095-2102.
7. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
8. Takeda Pharmaceutical Company Limited. Data on file. Kindly supplied through personal communication from Dr Alfonso Perez, VP Clinical Science, Takeda Pharamaceauticals, 18 December 2014. Updated 22 January 2015.
9. Lewis JD, Ferrara A, Strom BL, Quesenberry CPJr, Bilker WB, Peng T et al. KPNC 4th Interim Report, Cohort Study of Pioglitazone and Bladder Cancer (Study No. 01-03-TL-OPI-524) FDA Advice / Information request for sensitivity analysis and other analyses. Available at http://www.encepp.eu/encepp/openAttachment/documents.otherDocument-1/3652;jsessionid=P5CbTb3YKHyR2R20g217NK12hX2yX1TS1fQjbGn2x40HWqcy1PQt!1684841325 Last accessed 23 December 2014.
10. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58: 493-504.